Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Coeur D Alene, ID
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Park Ridge, IL
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Louisville, KY
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Metairie, LA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Baltimore, MD
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Boston, MA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Jackson, MS
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
St. Joseph, MO
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
St. Joseph, MO
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Henderson, NV
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Newark, NJ
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
New York, NY
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Ashville, NC
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Cleveland, OH
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Tulsa, OK
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Portland, OR
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Charleston, SC
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Chattanooga, TN
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Dallas, TX
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Seattle, WA
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Huntington, WV
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Huntington, WV
Click here to add this to my saved trials
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated:  11/15/2012
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Status: Enrolling
Updated: 11/15/2012
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
United Clinical Research Center, Inc.
mi
from
Anaheim, CA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
United Clinical Research Center, Inc.
mi
from
Anaheim, CA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Orange County Research Institute
mi
from
Anaheim, CA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Orange County Research Institute
mi
from
Anaheim, CA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Torrance Clinical Research
mi
from
Lomita, CA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Torrance Clinical Research
mi
from
Lomita, CA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Probe Clinical Research Corporation - Santa Ana
mi
from
Santa Ana, CA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Probe Clinical Research Corporation - Santa Ana
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Lake Internal Medicine Associates
mi
from
Eustis, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Lake Internal Medicine Associates
mi
from
Eustis, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Eastern Research, Inc.
mi
from
Hialeah, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Eastern Research, Inc.
mi
from
Hialeah, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Palm Springs Research Institute
mi
from
Hialeah, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Health Awareness
mi
from
Jupiter, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Health Awareness
mi
from
Jupiter, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Clinical Neuroscience Solutions, Inc
mi
from
Orlando, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Compass Research LLC
mi
from
Orlando, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Martin E. Hale, MD PA (Gold Coast Research LLC)
mi
from
Plantation, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Martin E. Hale, MD PA (Gold Coast Research LLC)
mi
from
Plantation, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Accord Clinical Research
mi
from
Port Orange, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Accord Clinical Research
mi
from
Port Orange, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
International Clinical Research
mi
from
Sanford, FL
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
International Clinical Research
mi
from
Sanford, FL
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
MediSphere Medical Research Center, LLC
mi
from
Knight, IN
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
MediSphere Medical Research Center, LLC
mi
from
Knight, IN
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Beacon Clinical Research, LLC
mi
from
Brockton, MA
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Beacon Clinical Research, LLC
mi
from
Brockton, MA
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Independent Clinical Researchers
mi
from
Las Vegas, NV
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Independent Clinical Researchers
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Clinical Study Center of Asheville, LLC
mi
from
Asheville, NC
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Clinical Study Center of Asheville, LLC
mi
from
Asheville, NC
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Wake Research Associates, LLC
mi
from
Raleigh, NC
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
The Center for Clinical Research
mi
from
Winston-Salem, NC
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
The Center for Clinical Research
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Hightop Physicians Inc./Medical Research Center
mi
from
Cincinnati, OH
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Hightop Physicians Inc./Medical Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Community Research
mi
from
Cincinnati, OH
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
Community Research - Anderson
mi
from
Cincinnati, OH
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
Community Research - Anderson
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated:  12/6/2012
New Horizons Clinical Research
mi
from
Cincinnati, OH
Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)
An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain
Status: Enrolling
Updated: 12/6/2012
New Horizons Clinical Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials